[Form 4] Lexeo Therapeutics, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Richard Nolan Townsend, Chief Executive Officer and Director of Lexeo Therapeutics, Inc. (LXEO), reported an acquisition of common stock on 09/12/2025 under the companys 2023 Employee Stock Purchase Plan. The Form 4 shows the purchase of 2,193 shares at a price of $2.644 per share. After this transaction, the reporting person beneficially owns 222,251 shares in total, a position that explicitly includes 131,092 Restricted Stock Units.

The filing is executed by an attorney-in-fact and states the ESPP transaction is exempt under Rule 16b-3(c) and 16b-3(d). No derivative transactions or other disposals are reported on this Form 4.

Positive

• Insider participation: CEO acquired 2,193 shares under the 2023 Employee Stock Purchase Plan at $2.644 per share
• Transparent reporting: Form 4 discloses total beneficial ownership of 222,251 shares and identifies 131,092 RSUs included in that total
• Exempt ESPP transaction: The filing states the purchase is exempt under Rule 16b-3(c) and 16b-3(d), indicating standard employee-plan treatment

Negative

• None.

Insights

Securities Analyst

TL;DR: CEO purchased 2,193 shares via the 2023 ESPP; beneficial ownership totals 222,251 shares including 131,092 RSUs.

The transaction is a routine, exempt ESPP purchase reported on Form 4, indicating insider participation in a company plan rather than a market-driven open-market buy. The purchase price of $2.644 per share and the disclosed total beneficial ownership provide clear, verifiable data points for tracking insider holdings. Because the filing discloses no option exercises, sales, or derivative activity, it appears to be a straightforward equity accumulation under employee benefits rather than a strategic market signal.

Corporate Governance Expert

TL;DR: Disclosure shows compliance with Section 16 reporting and use of ESPP; filing includes RSU holdings.

The Form 4 appropriately reports the ESPP acquisition and cites the Rule 16b-3 exemptions, reflecting standard governance and compliance practice for insider transactions. The inclusion of 131,092 Restricted Stock Units in the total beneficial ownership clarifies the composition of the reported stake. The document is limited to a non-derivative purchase and contains no additional governance actions or departures to suggest broader corporate changes.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Townsend Richard Nolan

(Last) (First) (Middle)

C/O LEXEO THERAPEUTICS, INC.

345 PARK AVENUE SOUTH, FLOOR 6

(Street)

NEW YORK NY 10010

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Lexeo Therapeutics, Inc. [ LXEO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
09/12/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/12/2025		A	V	2,193(1)	A	$2.644	222,251(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the Lexeo Therapeutics, Inc. 2023 Employee Stock Purchase Plan. This transaction is exempt under both Rule 16b-3(c) and Rule 16b-3(d).

2. Includes 131,092 Restricted Stock Units.

	/s/ Youjin Choi, Attorney-in-Fact	09/16/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Lexeo Therapeutics (LXEO) insider Richard Nolan Townsend report on 09/12/2025?

The Form 4 reports an acquisition of 2,193 common shares at $2.644 per share under the companys 2023 Employee Stock Purchase Plan.

How many shares does the reporting person beneficially own after the transaction?

The reporting person beneficially owns 222,251 shares following the reported transaction, which includes 131,092 Restricted Stock Units.

Was the ESPP transaction subject to Rule 16b-3 exemptions?

Yes. The filing states the acquisition is exempt under Rule 16b-3(c) and Rule 16b-3(d).

Did the Form 4 report any derivative transactions or dispositions?

No. The Form 4 discloses only a non-derivative acquisition of common stock and does not report derivative securities or disposals.

Who signed the Form 4 filing and when was it signed?

The Form 4 is executed by /s/ Youjin Choi, Attorney-in-Fact with a signature date of 09/16/2025.